WallStSmart

Ensysce Biosciences Inc (ENSC)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 49402% more annual revenue ($2.23B vs $4.50M). MRNA leads profitability with a -141.4% profit margin vs -280.5%. ENSC earns a higher WallStSmart Score of 28/100 (F).

ENSC

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -29.26

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSCUndervalued (+44.7%)

Margin of Safety

+44.7%

Fair Value

$0.74

Current Price

$0.40

$0.34 discount

UndervaluedFair: $0.74Overvalued
MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$135.25

Current Price

$142.77

$7.52 discount

UndervaluedFair: $135.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSC1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.2510/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$57.00B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

ENSC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.55M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1149.0%2/10

ROE of -1149.0% — below average capital efficiency

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSC

The strongest argument for ENSC centers on Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : ENSC

The primary concerns for ENSC are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

ENSC carries more volatility with a beta of 0.90 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

ENSC generates stronger free cash flow (-2M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENSC scores higher overall (28/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ensysce Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?